Eli Lilly developed Mounjaro, which the U.S. Food and Drug Administration approved in 2022 for type 2 diabetes.
Mounjaro is the brand name for tirzepatide. It is an injectable medicine that activates receptors associated with the hormones GIP and GLP-1, helping regulate blood glucose and appetite. The FDA approved it on May 13, 2022, for improving blood-sugar control alongside diet and exercise in adults with type 2 diabetes.
Eli Lilly and Company was founded in 1876 by Colonel Eli Lilly, a pharmacist and former Union Army officer. The company is headquartered in Indianapolis, Indiana, and has developed medicines across diabetes, oncology, neuroscience, immunology, and other fields.
Mounjaro is often confused with Zepbound, the same company’s tirzepatide brand approved for chronic weight management. Those products have related active ingredients but different brand indications. Eli Lilly’s market capitalization grew as investors assessed demand for its diabetes and obesity medicines, but market value changes daily with the share price.